SynthesisBMC anesthesiology2026
The effect of pregabalin for pain after third molar surgery: a systematic review and meta-analysis.
Synthesis in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPregabalin has been proposed as an adjunct for postoperative pain management following third molar surgery, but its analgesic efficacy, safety, and clinical applicability remain uncertain. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) ascertaining pregabalin for pain after third molar extraction.
methodsA systematic search was conducted across PubMed, Scopus, Web of Science, and Google Scholar up to January 2025. RCTs appraising pregabalin for postoperative pain following third molar surgery were included. The primary outcome was pain intensity (VAS) and the secondary outcome was adverse events (AEs). Data were pooled using a random-effects meta-analysis, with mean difference (MD) for pain scores and odds ratio (OR) for AEs, each with 95% confidence intervals (CIs). Risk of bias was assessed using the Cochrane RoB 2 tool.
resultsSix RCTs involving 545 patients undergoing third molar surgery were included. Of these, 170 patients (4 RCTs) contributed data to the quantitative synthesis. Pregabalin significantly mitigated postoperative pain compared with control (MD - 0.99, 95% CI - 1.46 to - 0.52, p < 0.00001), though substantial heterogeneity was observed (I²=91%). Subgroup analysis by timepoint revealed consistent but individually nonsignificant reductions in pain at 2-24 h postoperatively. Pregabalin use was linked to a higher risk of adverse events (OR 4.36, 95% CI 2.52-7.55, p < 0.00001, I²=77%), with a dose-response effect observed (ORs: 1.18 for 50 mg, 5.19 for 75 mg, 11.16 for 300 mg). Risk of bias was high or raised some concerns in three of the six included trials, with the certainty of evidence being limited by the substantial heterogeneity.
conclusionsPregabalin may provide a modest reduction in postoperative pain following third molar surgery; however, the clinical relevance and robustness of this benefit remain uncertain due to substantial heterogeneity and sensitivity to a single study. In contrast, pregabalin was consistently associated with an increased risk of adverse events. Therefore, the benefit-harm balance does not clearly support routine use of pregabalin as a first-line analgesic in this setting. Further high-quality, placebo-controlled RCTs with standardized dosing, comparator groups, and postoperative assessment timepoints are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.